Please provide your email address to receive an email when new articles are posted on . AI-analyzed fragmentomes and protein biomarkers better distinguished women with ovarian cancer in screening.

A study assessing an experimental cell-free DNA myelination liquid biopsy test was found to be 91% accurate at identifying early-stage epithelial ovarian cancer. A recent analysis investigating the ...

Ovarian cancer is often detected at a late stage, providing poor prognoses, while benign ovarian growths can lead to unnecessary surgeries. A new combined fragmentomic–protein biomarkers test could ...

Researchers are studying tests called liquid biopsies, which can provide vital information about cancer genes using only a blood sample. A blood test to find cancer even before it shows any symptoms ...

The global ovarian cancer diagnostics market is projected to grow at a compound annual growth rate (CAGR) of approximately 6% ...

While a common misconception about endometriosis is that it is simply a "menstruation disease," EndoFound says it's in fact a ...

A novel artificial intelligence (AI) protocol called DeepHRD was able to predict homologous recombination deficiency (HRD) in ovarian and breast cancers directly from routine histopathological slides.

A simulation study suggests that routine use of multicancer early detection tests could cut stage IV diagnoses of 14 cancers ...

Analysis of data from over 1.2 million US patients with gynecologic cancers between 2004 and 2020 revealed a significant shift towards surgical de-escalation, with increased use of minimally invasive ...

Stage 2 ovarian cancer is localized to the pelvis, with substages 2A and 2B indicating specific spread patterns. Diagnosis involves physical exams, imaging, blood tests, and biopsy to confirm cancer ...